Can a patient on Kadcyla safely undergo MRI the day after treatment?
Yes, a patient receiving Kadcyla (ado-trastuzumab emtansine) on Monday can safely undergo an MRI on Tuesday without any interference or contraindication related to the medication itself.
Key Points
Kadcyla does not contain any ferromagnetic components, metallic elements, or contrast agents that would interact with the MRI magnetic field or interfere with image acquisition. The drug is an antibody-drug conjugate consisting of trastuzumab linked to a cytotoxic agent (DM1), neither of which poses MRI safety concerns 1.
MRI Safety Considerations
The available evidence addresses MRI safety primarily in the context of:
- Cardiac implantable electronic devices - which require specific protocols but are unrelated to Kadcyla 2
- Gadolinium-based contrast agents - which have renal safety considerations but are separate from Kadcyla administration 3, 2, 3
- Metallic implants and devices - which require pre-screening but are not relevant to Kadcyla therapy 4, 5
None of these MRI safety guidelines identify any chemotherapeutic agents, including antibody-drug conjugates like Kadcyla, as contraindications to MRI scanning.
Clinical Context
While Kadcyla itself poses no MRI interference, consider these practical points:
Patient tolerability: Kadcyla can cause fatigue, nausea, and musculoskeletal pain 6. If the patient experiences significant acute infusion-related symptoms on Monday, they may have difficulty lying still for the MRI on Tuesday, but this is a comfort issue, not a safety contraindication.
Thrombocytopenia monitoring: Kadcyla commonly causes thrombocytopenia 1, 7. If the MRI requires gadolinium contrast and the patient has concurrent renal dysfunction, standard contrast safety protocols apply regardless of Kadcyla therapy 3.
Timing with other procedures: The only relevant timing consideration would be if the patient recently had breast reconstruction surgery, as delayed bleeding has been reported with Kadcyla 7, but this relates to surgical complications, not MRI safety.
Bottom Line
Proceed with the scheduled MRI on Tuesday. There is no pharmacologic, physical, or safety-based reason to delay or modify MRI imaging based on Kadcyla administration the previous day. Standard MRI safety screening protocols should be followed as with any patient, focusing on implanted devices, renal function (if contrast is planned), and ability to tolerate the procedure 4.